|
Advaxis Incorporated (OTCBB: ADXS) |
|
|
305 College Rd East
Princeton, NJ 08540 USA
phone:609.452.9813
fax:609.452.9818
|
|
| Symbol |
ADXS.OB |
| Exchange |
OTC BB |
| Founded |
2002 |
| Employees |
12 |
|
|
| www.advaxis.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Biotechnology to treat cancer and infectious disease |
|
| Management |
| Thomas A. Moore,
Chairman, CEO;
John Rothman, Ph.D.,
EVP of Science and Operations;
Mark Rosenblum,
Chief Financial Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| Immunotherapy, cancer, infectious disease, breast, prostate, HPV |
|
|
|
| Description |
|
Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. The Company’s novel platform technology utilizes a modified infectious microorganism, live attenuated Listeria monocytogenes (Lm), which is bio-engineered to secrete an antigen/adjuvant fusion (Lm-LLO) protein and thereby activate numerous aspects of the immune system simultaneously. Lm-LLO-based immunotherapy is able to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, and changing the tumor microenvironment by increasing tumor infiltrating killer T-cells and decreasing Tregs/MDSCs. Effects include innate immunity, enactment of both arms of the adaptive immune response, and many non-classical immune responses. This later-stage biotechnology company has over fifteen distinct constructs in various stages of development, some directly developed by the Company and others through strategic collaborations with recognized centers of excellence. |
|
| Products / Services |
ADXS-HPV is being developed with indications for recurrent cervical cancer, cervical intraepithelial neoplasia (CIN), and head & neck cancer.
ADXS-PSA is in pre-clinical development for the treatment of prostate cancer.
ADXS-HER2 is in pre-clinical development for the treatment of HER2 over-expressing cancers, such as certain types of breast cancer, and is being used in a Phase 1 study for canine osteosarcoma in companion dogs.
|
|
| Technology / Differentiation |
| Advaxis immunotherapies are based upon a novel platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bio-engineered to secrete an antigen/adjuvant fusion (Lm-LLO) protein. Lm-LLO consists of a truncated fragment of the Lm protein listeriolysin (LLO), fused to target antigens of interest. Lm-LLO stimulates a powerful immune response not only to Lm which is inherent in humans, but redirects this same response to the target antigen(s). Lm-LLO based immunotherapy is designed to generate a more comprehensive immune response by serving as its own adjuvant, directing antigen presentation, and changes the tumor microenvironment by increasing tumor infiltrating killer T-cells and decreasing Tregs/MDSCs. |
|
| Market / Customers |
Advaxis is in development stages to create immunotherapies that can treat patients for HPV-caused cancer and other cancers and infectious diseases.
|
|
| Competitors / Substitutes / Alternatives |
Geovax (Otcbb: GOVX)
Dendreon (Nasdaq: DNDN)
ImmunoCellular (Otcbb: IMUC)
Oncolytics (Otcbb: ONCY)
Provectus (Otcbb: PVCT)
CellGene (Nsdaq: CELG)
|
|
| Strategy |
Technology - To use our proprietary, versatile platform as the foundation for a continuous pipeline of active immunotherapies that target multiple cancers and infectious diseases.
Clinical - To demonstrate the safety and efficacy of our active immunotherapies through company- and government-sponsored trials and collaborations with leading institutions and organizations.
Shareholder - To maximize value by leveraging the technology, developing improved constructs, out-licensing immunotherapies, and building a broad & defensible patent portfolio.
|
|
| Funding |
| Advaxis continues to raise money through grants and partnerships. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
